ARB drugs surpass calcium antagonists

Published: 2011-01-26 07:00:00

Updated: 2011-01-26 07:00:00

The market share of angiotensin-2 receptor blocks (ARB), such as Almetec and Cozzar, has gained momentum, outpacing the former No. 1 drug on the antihypertensive market, Norvasc, by a wide margin.

ARB drugs accounted for about 50 percent, to 836.8 billion won in domestic 1.5 trillion won marke...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK